Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA prenatal nutrition survey

This article was originally published in The Tan Sheet

Executive Summary

FDA intends to survey healthcare professionals to determine "what information, advice and recommendations they are offering to pregnant women" about nutrition and food safety, according to a notice published in the Federal Register June 2. Specifically, the agency is interested in learning about the following topics: methyl mercury and seafood consumption, listeriosis prevention, weight control and nutrition, dietary supplement usage, food allergies, toxoplasmosis prevention and infant feeding practices. FDA will use the information to determine whether advice issued by the agency is reaching relevant healthcare providers and whether the providers are then using this information to educate their patients. "FDA will also use the survey to get a better understanding of what resources health care professionals use to stay abreast of current practices for caring for pregnant women," the agency says. That information will help "FDA provide timely recommendations to health care professionals that will reach the largest audience"...

You may also be interested in...

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Health And Wellness Trademark Review 22 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts